151 related articles for article (PubMed ID: 38538206)
21. Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran).
Sinning D; Landmesser U
Curr Cardiol Rep; 2020 Oct; 22(12):176. PubMed ID: 33089390
[TBL] [Abstract][Full Text] [Related]
22. Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia.
Khan SA; Naz A; Qamar Masood M; Shah R
Am J Cardiol; 2020 Nov; 134():69-73. PubMed ID: 32892993
[TBL] [Abstract][Full Text] [Related]
23. Inclisiran-A Revolutionary Addition to a Cholesterol-Lowering Therapy.
Dec A; Niemiec A; Wojciechowska E; Maligłówka M; Bułdak Ł; Bołdys A; Okopień B
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047830
[TBL] [Abstract][Full Text] [Related]
24. Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis.
Imran TF; Khan AA; Has P; Jacobson A; Bogin S; Khalid M; Khan A; Kim S; Erqou S; Choudhary G; Aspry K; Wu WC
PLoS One; 2023; 18(12):e0295359. PubMed ID: 38055686
[TBL] [Abstract][Full Text] [Related]
25. [Inclisiran - a new era in lipid-lowering therapy].
Voevoda MI; Gurevich VS; Ezhov MV; Sergienko IV
Kardiologiia; 2022 Jun; 62(6):57-62. PubMed ID: 35834343
[TBL] [Abstract][Full Text] [Related]
26. Translational Population-Pharmacodynamic Modeling of a Novel Long-Acting siRNA Therapy, Inclisiran, for the Treatment of Hypercholesterolemia.
Gosselin NH; Schuck VJA; Barriere O; Kulmatycki K; Margolskee A; Smith P; He Y
Clin Pharmacol Ther; 2023 Feb; 113(2):328-338. PubMed ID: 36281788
[TBL] [Abstract][Full Text] [Related]
27. Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9-A Narrative Review.
Merćep I; Friščić N; Strikić D; Reiner Ž
Cardiovasc Ther; 2022; 2022():8129513. PubMed ID: 35237348
[TBL] [Abstract][Full Text] [Related]
28. Development of Novel siRNA Therapeutics: A Review with a Focus on Inclisiran for the Treatment of Hypercholesterolemia.
Ebenezer O; Comoglio P; Wong GK; Tuszynski JA
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835426
[TBL] [Abstract][Full Text] [Related]
29. Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1.
Landmesser U; Haghikia A; Leiter LA; Wright RS; Kallend D; Wijngaard P; Stoekenbroek R; Kastelein JJ; Ray KK
Cardiovasc Res; 2021 Jan; 117(1):284-291. PubMed ID: 32243492
[TBL] [Abstract][Full Text] [Related]
30. Small interfering ribonucleic acid for cholesterol lowering - Inclisiran: Inclisiran for cholesterol lowering.
Soffer D; Stoekenbroek R; Plakogiannis R
J Clin Lipidol; 2022; 16(5):574-582. PubMed ID: 35909047
[TBL] [Abstract][Full Text] [Related]
31. [Long-lasting LDL-C lowering: silence at last].
Achard M; Buhayer A; Dobretz K; Ehret G; Mach F
Rev Med Suisse; 2021 May; 17(740):1039-1046. PubMed ID: 34042340
[TBL] [Abstract][Full Text] [Related]
32. Small interfering RNA to proprotein convertase subtilisin/kexin type 9: transforming LDL-cholesterol-lowering strategies.
Brandts J; Ray KK
Curr Opin Lipidol; 2020 Aug; 31(4):182-186. PubMed ID: 32487819
[TBL] [Abstract][Full Text] [Related]
33. A systematic review and meta-analysis of tolerability, cardiac safety and efficacy of inclisiran for the therapy of hyperlipidemic patients.
Dutta S; Shah R; Singhal S; Singh S; Piparva K; Katoch CDS
Expert Opin Drug Saf; 2024 Feb; 23(2):187-198. PubMed ID: 38063346
[TBL] [Abstract][Full Text] [Related]
34. New Pharmacological Approaches to Target PCSK9.
Catapano AL; Pirillo A; Norata GD
Curr Atheroscler Rep; 2020 Jun; 22(7):24. PubMed ID: 32495301
[TBL] [Abstract][Full Text] [Related]
35. High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany.
Makhmudova U; Schatz U; Perakakis N; Kassner U; Schumann F; Axthelm C; Stürzebecher P; Sinning DL; Doevelaar A; Rohn B; Westhoff T; Vogt A; Scholl M; Kästner U; Geiling JA; Stach K; Mensch J; Lorenz E; Paitazoglou C; Eitel I; Baessler A; Steinhagen-Thiessen E; Koenig W; Schulze PC; Landmesser U; Laufs U; Weingärtner O;
Clin Res Cardiol; 2023 Nov; 112(11):1639-1649. PubMed ID: 37422840
[TBL] [Abstract][Full Text] [Related]
36. Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins.
Warden BA; Duell PB
J Cardiovasc Pharmacol; 2021 Aug; 78(2):e157-e174. PubMed ID: 33990512
[TBL] [Abstract][Full Text] [Related]
37. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial.
Ray KK; Troquay RPT; Visseren FLJ; Leiter LA; Scott Wright R; Vikarunnessa S; Talloczy Z; Zang X; Maheux P; Lesogor A; Landmesser U
Lancet Diabetes Endocrinol; 2023 Feb; 11(2):109-119. PubMed ID: 36620965
[TBL] [Abstract][Full Text] [Related]
38. Inclisiran: Government's strategy to promote cholesterol lowering drug after Brexit was "spectacular failure," says insider.
Cohen D; McCartney M
BMJ; 2024 Jan; 384():q90. PubMed ID: 38216214
[No Abstract] [Full Text] [Related]
39. Inclisiran: How Widely and When Should We Use It?
Pirillo A; Catapano AL
Curr Atheroscler Rep; 2022 Oct; 24(10):803-811. PubMed ID: 35877035
[TBL] [Abstract][Full Text] [Related]
40. Inclisiran (Leqvio) for LDL-cholesterol lowering.
Med Lett Drugs Ther; 2022 Mar; 64(1646):43-45. PubMed ID: 35294427
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
